Posted 10 June 2005

General Information

Transgene: Mutant tau-P301L was obtained by site-directed mutagenesis of tau-4R/2N and cloned into the blunted XhoI site of the thy1 gene expression cassette. The construct was linearized with NotI and PvuI and injected into prenuclear mouse embryos (0.5-day) of the FVB/N strain.

Mutation: Human Tau-P301L in the Tau-4R/2N isoform

Promoter: mouse Thy1

Mouse strain: FVB/N

Phenotype

Neuropathological Analysis:

Expression level, similar to Tau-4R/2N. Axonal dilations, absent. Intra-neuronal tau aggregates (NFT), progressive > 6 months, severe at 9-12 months.

Behavioral:

Clasping, impaired. Rotarod, normalBeam walk, failed >9 months. Mean life span <12 months.

Availability

Licensing/academic distribution contact information:

Paul Van Dun
Director - KULeuvenR&D
Groot Begijnhof 59
B-3000 Leuven Belgium
tel +32 16 326508
fax +32 16 326515
Email: Paul.Vandun@lrd.kuleuven.ac.be
Web site: http://www.kuleuven.ac.be/lrd

Patents: none

References

Primary:

Terwel D, Lasrado R, Snauwaert J, Vandeweert E, Van Haesendonck C, Borghgraef P, Van Leuven F.Changed conformation of mutant tau-P301L underlies the moribund tauopathy, absent in progressive, non-lethal axonopathy of tau-4R/2N transgenic mice. J Biol Chem (2005) 280: 3963-3973. Abstract.